- Home
- KZR vs NRXS Comparison
KZR vs NRXS Comparison
Compare KZR & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KZR | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 49.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KZR | NRXS |
|---|---|---|
| Price | $6.03 | $4.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | 38.0K | ★ 106.0K |
| Earning Date | 03-24-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $3.53 | $1.33 |
| 52 Week High | $6.62 | $6.20 |
Technical Indicators
Market Signals| Indicator | KZR | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 50.06 |
| Support Level | $6.05 | $4.13 |
| Resistance Level | $6.24 | $4.82 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 0.04 | 23.78 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).